The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Short Antisense Oligonucleotides with Novel 2′−4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Open accessAbstract
The potency of second generation antisense oligonucleotides (ASOs) in animals was increased 3- to 5 -fold (ED(50) approximately 2-5 mg/kg) without producing hepatotoxicity, by reducing ASO length (20-mer to 14-mer) and by employing novel nucleoside modifications that combine structural elements of 2'-O-methoxyethyl residues and locked nucleic acid. The ability to achieve this level of potency without any formulation agents is remarkable and likely to have a significant impact on the future design of ASOs as therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Freier, S. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.22.4429 · Cited by 692
Obika, S., Nanbu, D., Hari, Y., Morio, K.-I., In, Y., Ishida, T., & Imanishi, T. (1997) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10322-7 · Cited by 610
Physicochemical properties of phospborothioate oligodeoxynucleotides
Stein, C. A., Subasinghe, C., Shinozuka, K., & Cohen, J. S. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.8.3209 · Cited by 591
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Self-citationPhosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., & Crooke, R. M. (2006) · Circulation · doi:10.1161/circulationaha.105.606442 · Cited by 358
Wengel, J. (1999) · Accounts of Chemical Research · doi:10.1021/ar980051p · Cited by 335
Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., & Perera, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400492-jlr200 · Cited by 225
Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice
Butler, M., McKay, R. A., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, S., & Monia, B. P. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1028 · Cited by 216
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
Crystal structure and improved antisense properties of 2'-O-(2-methoxyethyl)-RNA.
Manoharan, M., Egli, M., Teplova, M., Minasov, G., Tereshko, V. A., Inamati, G. B., & Cook, P. D. (1999) · Nature Structural Biology · doi:10.1038/9304 · Cited by 178
“Antisense Drug Technology. Principles, Strategies, and Applications”
Lee, G. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00090-5 · Cited by 135
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary, R. S., Yu, R. Z., & Levin, A. A. (2001) · PubMed · Cited by 133
Potent and selective inhibition of gene expression by an antisense heptanucleotide
Wagner, R. W., Matteucci, M. D., Grant, D., Huang, T., & Froehler, B. C. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-840 · Cited by 114
Seth, P. P., Siwkowski, A., Allerson, C. R., Vàsquez, G., Lee, S. S., Prakash, T. P., Kinberger, G. A., Migawa, M. T., Gaus, H. J., Bhat, B., et al. (2008) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrn280 · Cited by 105
Self-citationTissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
Yu, R. Z., Geary, R. S., Monteith, D., Matson, J. E., Truong, L., Fitchett, J. R., & Levin, A. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10473 · Cited by 104
Toxicologic Properties of 2-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man
Henry, S. P., Kim, T., Kramer-Stickland, K., Zanardi, T. A., Fey, R. A., & Levin, A. A. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-20 · Cited by 37
Geary, R. S., Yu, R. Z., Siwkowski, A., et al. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-19 · Cited by 32
Self-citationAntisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012
Akdim, F., Harchaoui, K. E., Stroes, E. S. G., & Kastelein, J. J. P. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.387 · Cited by 7
Cited by
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationThe chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Self-citationThe Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Self-citationA Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells
Cecchelli, R., Aday, S., Sevin, E., Almeida, C., Culot, M., Dehouck, L., Coisne, C., Engelhardt, B., Dehouck, M.-P., & Ferreira, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099733 · Cited by 349
Metadata
- Authors
- Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., & Swayze, E. E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-12-16
- Volume
- 52
- Issue
- 1
- Pages
- 10-13
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1964514885
- Cited by
- 266
- References
- 20
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.